An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.

The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

660

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China, 510080
        • Guangdong Provincial People's Hospital
        • Principal Investigator:
          • Yilong Wu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
  2. At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
  3. The ECOG score was 0 or 1.
  4. Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).
  5. Adequate bone marrow and organ function.

Exclusion Criteria:

  1. Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
  2. Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.
  3. Participants with active, known or suspected autoimmune diseases.
  4. Other malignant tumors within 5 years before screening.
  5. Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
  6. Participants with severe cardiovascular and cerebrovascular diseases.
  7. There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
  8. Arterial and venous thrombosis events occurred within 3 months before the first administration.
  9. HIV test positive.
  10. Participants with active hepatitis B or C.

1.Evidence of active tuberculosis infection within 1 year before the first administration.

12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.

14. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group A1-1adebrelimab + SHR-A2009

adebrelimab + SHR-A2009

adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009 (shorter-interval regimen arm)

Active Comparator: group A1-2 paclitaxel or pemetrexed combined with carboplatin +adebrelimab

paclitaxel or pemetrexed combined with carboplatin +adebrelimab

Experimental: group1 A2-1adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009

adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009 (shorter-interval regimen arm)

Experimental: group2 A2-2adebrelimab + SHR-A2009 (shorter-interval regimen arm)

adebrelimab + SHR-A2009

adebrelimab + SHR-A2009 (longer-interval regimen arm)

adebrelimab + SHR-A2009 (shorter-interval regimen arm)

Active Comparator: group A2-3 adebrelimab

adebrelimab

Experimental: group1 A3-1 adebeliizumab + SHR-A2009 (longer-interval regimen arm)

adebeliizumab + SHR-A2009 (longer-interval regimen arm)

adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

Experimental: group2 A3-2 adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

adebeliizumab + SHR-A2009 (longer-interval regimen arm)

adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

Active Comparator: group A3-3 adebeliizumab + platinum-containing double chemotherapy

adebeliizumab + platinum-containing double chemotherapy

Experimental: group B1-1 almonertinib combined with SHR-A2009 (longer-interval regimen arm)

almonertinib combined with SHR-A2009 (longer-interval regimen arm)

almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

Experimental: group B1-2 almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

almonertinib combined with SHR-A2009 (longer-interval regimen arm)

almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

Active Comparator: group B1-3 almonertinib

almonertinib

Experimental: group B2-1 SHR-A2009 combined with almonertinib

SHR-A2009 combined with almonertinib

Active Comparator: group B2-2 almonertinib monotherapy

almonertinib monotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Part A1 : pCR rate;
Time Frame: about 24 months
about 24 months
Part A2 : 2-year DFS rate;
Time Frame: about 24 months
about 24 months
Part A3 : pCR rate and 18-month EFS rate;
Time Frame: about 18 months
about 18 months
Part B1 : 2-year DFS rate.
Time Frame: about 24 months
about 24 months
Part B2 : MPR rate.
Time Frame: about 24 months
about 24 months

Secondary Outcome Measures

Outcome Measure
Time Frame
The incidence and grade of adverse events;
Time Frame: about 48 months
about 48 months
surgical complications;
Time Frame: about 24 months
about 24 months
EFS
Time Frame: about 24 months ;
about 24 months ;
ORR;
Time Frame: about 24 months
about 24 months
DFS and DFS rates;
Time Frame: about 24 months
about 24 months
OS ;
Time Frame: about 48 months
about 48 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 30, 2026

Primary Completion (Estimated)

December 30, 2028

Study Completion (Estimated)

December 30, 2030

Study Registration Dates

First Submitted

September 30, 2026

First Submitted That Met QC Criteria

September 30, 2026

First Posted (Actual)

October 7, 2026

Study Record Updates

Last Update Posted (Actual)

November 9, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SHR-A2009-203

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.